99,785 results match your criteria Hepatitis C


Incidence, Mortality Features and Lifetime Risk Estimation of Digestive Tract Cancers in an Urban District of Shanghai, China.

J Epidemiol Glob Health 2022 Jun 25. Epub 2022 Jun 25.

School of Public Health, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.

Digestive tract cancers are the common cause of cancer deaths in both China and worldwide. This study aimed to describe the burden, recent trends and lifetime risks in the incidence and mortality of digestive tract cancers in an urban district of Shanghai, China. Our study extracted data on stomach, colon, rectum and liver cancers diagnosed in Changning District between 2010 and 2019 from the Shanghai Cancer Registry. Read More

View Article and Full-Text PDF

Performance of rapid test for antibodies to hepatitis C virus (anti-HCV) in hemodialysis patients and kidney transplant recipients.

Int J Artif Organs 2022 Jun 24:3913988221104834. Epub 2022 Jun 24.

Division of Gastroenterology, Federal University of São Paulo, Sao Paulo, Brazil.

Rapid tests (RT) have been widely used for screening of hepatitis C virus (HCV) in general population, but its performance in hemodialysis (HD) patients and mainly in kidney-transplant recipients (RTx) is less known. The aim of this study was to evaluate the accuracy of RT for detection of anti-HCV in HD and RTx patients. Patients were prospectively included subdivided in four groups according to the positivity for anti-HCV detected by conventional serology: (1) HD patients anti-HCV +, (2) HD patients anti-HCV -, (3) RTx patients anti-HCV +, and (4) RTx patients anti-HCV -. Read More

View Article and Full-Text PDF

Association of Equiliberative Nucleoside Transporter (ENT) with liver fibrosis stage in Hepatitis-C.

J Pak Med Assoc 2022 Jun;72(6):1080-1085

Department of Pathology, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan.

Objective: To evaluate the pattern of equiliberative nucleoside transporters in viral hepatitis responding and non-responding patients, to correlate the liver fibrosis stage with the pattern among the non-responders, and to correlate the equiliberative nucleoside transporter status with housekeeping hypoxanthine-guanine phosphoribosyltransferase gene.

Method: The comparative cross-sectional study was conducted at the Molecular Biology and Genetics Department, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan, from March to August 2018, and comprised adult hepatitis C virus patients of either gender who completed six months of treatment. They were assessed for response to therapy in terms of the presence of the viral load in their serum by using real time polymerase chain reaction, and divided into responder group A and non-responder group B. Read More

View Article and Full-Text PDF

Recipient Selection Criteria for Facial Transplantation: A Systematic Review.

Ann Plast Surg 2022 Jul;89(1):105-112

Hansjörg Wyss Department of Plastic Surgery, New York University, New York, NY.

Background: Recipient selection is an important determinant of surgical outcomes in facial transplantation (FT). Appropriately, each FT program develops their own guidelines for recipient selection criteria. Currently, there is no resource to simultaneously assess and identify similarities and differences between these guidelines. Read More

View Article and Full-Text PDF

Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis 113 characteristics (excluding spaces).

Hepatol Res 2022 Jun 24. Epub 2022 Jun 24.

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

Aim: Hepatocellular carcinoma (HCC) after sustained virologic response (SVR) has been observed even in hepatitis C virus (HCV) patients without advanced liver fibrosis. Identifying predictors for HCC incidence in patients without advanced liver fibrosis will enable efficient post-SVR HCC surveillance. This study aimed to develop a scoring system to predict the incidence of HCC after SVR in HCV patients without advanced liver fibrosis. Read More

View Article and Full-Text PDF

Effectiveness and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir as a Hepatitis C Virus Infection Salvage Therapy in the Real World: A Systematic Review and Meta-analysis.

Infect Dis Ther 2022 Jun 24. Epub 2022 Jun 24.

Department of Pharmacy, Beijing Youan Hospital, Capital Medical University, No. 8 Xitoutiao, Youanmenwai, Fengtai District, Beijing, China.

Introduction: Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) is the first direct-acting antiviral (DAA) therapy approved for patients who have previously failed a DAA-containing regimen including NS5A inhibitors. In clinical trials, SOF/VEL/VOX was associated with high rates of sustained virologic response at post-treatment week 12 (SVR12) and was well tolerated. However, the effectiveness and safety of SOF/VEL/VOX in the real world remained uncertain. Read More

View Article and Full-Text PDF

Can Treatment, Without Prevention, Eliminate Hepatitis C Among Men Who Have Sex With Men?

J Viral Hepat 2022 Jun 24. Epub 2022 Jun 24.

Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

View Article and Full-Text PDF

Treatment of Hepatitis Delta and HIV Infection.

Liver Int 2022 Jun 24. Epub 2022 Jun 24.

Public Health Regional Laboratory, Hospital Isabel Zendal, Madrid, Spain.

Hepatitis delta virus (HDV) is a defective agent that only infects individuals with hepatitis B virus (HBV). Around 5-10% of chronic hepatitis B patients worldwide are superinfected with HDV, which means 15-25 million people. Hepatitis delta is the most severe of all chronic viral hepatitis, leading to cirrhosis, liver cancer and/or transplantation in most patients. Read More

View Article and Full-Text PDF

Utilizing Telemedicine and Modified Fibrosis Staging Protocols to Maintain Treatment Initiation and Adherence Among Hepatitis C Patients During the COVID-19 Pandemic.

J Prim Care Community Health 2022 Jan-Dec;13:21501319221108000

Boston Medical Center, Boston, MA, USA.

The COVID-19 pandemic exacerbated the decline in Hepatitis C Virus (HCV) screening and treatment globally in part due to lockdowns and restrictions at healthcare centers. The goal of this retrospective cohort study was to assess the effectiveness of an updated workflow implemented at Boston Medical Center (BMC) HCV clinics. Revised workflow incorporated appointments via telemedicine, transitioning to blood test-based fibrosis scoring, and delivering medication by mail to mitigate the lack of in-person services. Read More

View Article and Full-Text PDF

Preliminary Study on the Possibility to Detect Virus Nucleic Acids in Post-Mortem Blood Samples.

Front Biosci (Landmark Ed) 2022 Jun;27(6):183

Department of Diagnostics and Public Health, Legal Medicine Section, University of Verona, 37134 Verona, Italy.

Background: In many forensic cases, the medical records of the deceased are not available at the time of the autopsy; therefore, no information about the deceased's state of health, including any infectious diseases contracted during life, is accessible. The detection of some of the principal viral infections, such as hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus type 1 (HIV-1), could contribute to determining causes of death and interesting applications could be found in medico-legal practice, such as occupational risk assessment. To date, accurate and sensitive serological and molecular assays capable of detecting these viruses have been validated on biological samples taken from living beings, while their efficiency on forensic post-mortem biological samples has yet to be thoroughly assessed. Read More

View Article and Full-Text PDF

Hepatitis C is associated with more adverse pregnancy outcomes than hepatitis B: A 7-year national inpatient sample study.

Hepatol Commun 2022 Jun 24. Epub 2022 Jun 24.

Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Prior international studies have shown mixed results regarding the association of hepatitis B and hepatitis C with adverse pregnancy outcomes. We performed an updated evaluation of the prevalence of associated adverse pregnancy outcomes and evaluated trends over time of diagnosis of chronic hepatitis B (HBV) and chronic hepatitis C (HCV) in pregnant women in a national database. All pregnant women with HBV and HCV were identified from the National Inpatient Sample database 2012 to 2018. Read More

View Article and Full-Text PDF

Direct-Acting Antiviral Agents for Hepatitis C Virus Infection-From Drug Discovery to Successful Implementation in Clinical Practice.

Viruses 2022 Jun 17;14(6). Epub 2022 Jun 17.

Department of Gastroenterology, Hepatology and Endocrinology, Medical High School Hannover, 30625 Hannover, Germany.

Today, hepatitis C virus infection affects up to 1.5 million people per year and is responsible for 29 thousand deaths per year. In the 1970s, the clinical observation of unclear, transfusion-related cases of hepatitis ignited scientific curiosity, and after years of intensive, basic research, the hepatitis C virus was discovered and described as the causative agent for these cases of unclear hepatitis in 1989. Read More

View Article and Full-Text PDF

Hepatitis C Virus Epidemiology in Lithuania: Situation before Introduction of the National Screening Programme.

Viruses 2022 May 30;14(6). Epub 2022 May 30.

Department of Gastroenterology, Lithuanian University of Health Sciences, LT50161 Kaunas, Lithuania.

In 2022, the Lithuanian health authorities decided to pay general practitioners a fee for performing serological tests for hepatitis C virus (HCV) antibodies in the population born from 1945 to 1994 once per life and annual HCV testing for PWID and HIV infected patients. This study aimed to assess trends in HCV-related mortality in the country and the prevalence of HCV infection among patients with liver diseases and evaluate possibilities of screening for HCV infection at a primary health care center. Age-standardized mortality rates in 2010-2020 were calculated for deaths caused by chronic hepatitis C and some liver diseases. Read More

View Article and Full-Text PDF

Burden and Trends of Acute Viral Hepatitis in Asia from 1990 to 2019.

Viruses 2022 May 28;14(6). Epub 2022 May 28.

Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China.

Asia has a very high burden of acute hepatitis; thus, a comprehensive study of the current burden and long-term trends of acute hepatitis in Asia is needed. We aimed to assess the current status and trends from 1990 to 2019 of acute hepatitis burden in Asia, using the data from the Global Burden of Diseases Study 2019 (GBD 2019) results. We used the data from the GBD 2019. Read More

View Article and Full-Text PDF

Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis.

Viruses 2022 May 25;14(6). Epub 2022 May 25.

Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei 100, Taiwan.

Ropeginterferon alfa-2b is a novel mono-pegylated and extra-long-acting interferon, being developed for the treatment of myeloproliferative neoplasm (MPN) and chronic viral hepatitis. It has a favorable pharmacokinetic profile and less frequent dosing schedule, i.e. Read More

View Article and Full-Text PDF

Near-Infrared Spectroscopy as a Potential COVID-19 Early Detection Method: A Review and Future Perspective.

Sensors (Basel) 2022 Jun 10;22(12). Epub 2022 Jun 10.

Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia Health Campus, Kubang Kerian 16150, Kelantan, Malaysia.

The coronavirus disease 2019 (COVID-19) pandemic is a worldwide health anxiety. The rapid dispersion of the infection globally results in unparalleled economic, social, and health impacts. The pathogen that causes COVID-19 is known as a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Read More

View Article and Full-Text PDF

Pharmacophore-Based Discovery of Viral RNA Conformational Modulators.

Pharmaceuticals (Basel) 2022 Jun 14;15(6). Epub 2022 Jun 14.

Centro de Investigación Traslacional San Alberto Magno, Universidad Católica de Valencia San Vicente Mártir, C/Quevedo 2, 46001 Valencia, Spain.

New RNA-binding small-molecule scaffolds are needed to unleash the pharmacological potential of RNA targets. Here we have applied a pharmacophore-based virtual screening approach, seldom used in the RNA recognition field, to identify novel conformational inhibitors of the hepatitis C virus internal ribosome entry site. The conformational effect of the screening hits was assessed with a fluorescence resonance energy transfer assay, and the affinity, specificity, and binding site of the ligands were determined using a combination of fluorescence intensity and NMR spectroscopy experiments. Read More

View Article and Full-Text PDF

Seroprevalence of Transfusion Transmissible Infections and Associated Risk Factors in Hospitalized Patients before Transfusion in Jinling Hospital Nanjing University: A Three-Year Retrospective Study.

Pathogens 2022 Jun 20;11(6). Epub 2022 Jun 20.

Department of Blood Transfusion Medicine, School of Medicine, Jinling Hospital, Nanjing University, Nanjing 210016, China.

Transfusion-transmitted infections (TTIs), such as hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and treponema pallidum (TP), must be detected before blood transfusion. However, few studies have been conducted on the prevalence and accuracy of positive results in hospitalized patients. The purpose of this study was to investigate the real seroprevalence of TTIs among patients before blood transfusion and analyze the characteristics of false-positive results in Jinling Hospital, Nanjing University, China. Read More

View Article and Full-Text PDF

Probe Capture Enrichment Methods for HIV and HCV Genome Sequencing and Drug Resistance Genotyping.

Pathogens 2022 Jun 16;11(6). Epub 2022 Jun 16.

National HIV and Retrovirology Laboratories, National Microbiology Laboratory at JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada.

Human immunodeficiency virus (HIV) infections remain a significant public health concern worldwide. Over the years, sophisticated sequencing technologies such as next-generation sequencing (NGS) have emerged and been utilized to monitor the spread of HIV drug resistance (HIVDR), identify HIV drug resistance mutations, and characterize transmission dynamics. Similar applications also apply to the Hepatitis C virus (HCV), another bloodborne viral pathogen with significant intra-host genetic diversity. Read More

View Article and Full-Text PDF

SARS-CoV-2 Mutant Spectra at Different Depth Levels Reveal an Overwhelming Abundance of Low Frequency Mutations.

Pathogens 2022 Jun 8;11(6). Epub 2022 Jun 8.

Structural Biology Department, Institut de Biología Molecular de Barcelona CSIC, 08028 Barcelona, Spain.

Populations of RNA viruses are composed of complex and dynamic mixtures of variant genomes that are termed mutant spectra or mutant clouds. This applies also to SARS-CoV-2, and mutations that are detected at low frequency in an infected individual can be dominant (represented in the consensus sequence) in subsequent variants of interest or variants of concern. Here we briefly review the main conclusions of our work on mutant spectrum characterization of hepatitis C virus (HCV) and SARS-CoV-2 at the nucleotide and amino acid levels and address the following two new questions derived from previous results: (i) how is the SARS-CoV-2 mutant and deletion spectrum composition in diagnostic samples, when examined at progressively lower cut-off mutant frequency values in ultra-deep sequencing; (ii) how the frequency distribution of minority amino acid substitutions in SARS-CoV-2 compares with that of HCV sampled also from infected patients. Read More

View Article and Full-Text PDF

A Rare Case of Didanosine-Induced Mid-Peripheral Chorioretinal Atrophy Identified Incidentally 11 Years after the Drug Cessation.

Medicina (Kaunas) 2022 May 30;58(6). Epub 2022 May 30.

Department of Ophthalmology, Centre Hospitalier Regional Universitaire de Tours, Bretonneau Hospital, 37000 Tours, France.

This article aims to describe a unique case of didanosine-induced retinal degeneration that was discovered 11 years after the drug withdrawal. The patient is a 42-year-old woman with a medical history of HIV and hepatitis C virus since 2004. She has been prescribed antiretroviral therapy since then. Read More

View Article and Full-Text PDF

Can Telemedicine Optimize the HCV Care Cascade in People Who Use Drugs? Features of an Innovative Decentralization Model and Comparison with Other Micro-Elimination Strategies.

Biology (Basel) 2022 May 24;11(6). Epub 2022 May 24.

Hepatology Unit, Ospedale Evangelico Betania, 80147 Naples, Italy.

People who use drugs (PWUDs) are a crucial population in the global fight against viral hepatitis. The difficulties in linkage to care, the low adherence to therapy, the frequent loss to follow-up and the high risk of re-infection make the eradication process of the hepatitis C virus (HCV) really hard in this viral reservoir. Several management and treatment models have been tested with the aim of optimizing the HCV care cascade in PWUDs. Read More

View Article and Full-Text PDF

Telemedicine Improves HCV Elimination among Italian People Who Use Drugs: An Innovative Therapeutic Model to Increase the Adherence to Treatment into Addiction Care Centers Evaluated before and during the COVID-19 Pandemic.

Biology (Basel) 2022 May 24;11(6). Epub 2022 May 24.

Liver Unit, Ospedale Evangelico Betania, 80147 Naples, Italy.

People who use drugs (PWUDs) are generally considered "hard-to-treat" patients, due to adherence to HCV antiviral therapy or re-infection concerns. Linkage-to-care still remains a significant gap for HCV elimination, worsened by the COVID-19 pandemic. To reduce time-to-treat and improve treatment adherence, we have developed a patient-tailored model-of-care, decentralized within the addiction center and supervised remotely by hepatologists. Read More

View Article and Full-Text PDF

Ten steps to eliminating hepatitis C in hospitals.

Nat Rev Gastroenterol Hepatol 2022 Jun 23. Epub 2022 Jun 23.

Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.

View Article and Full-Text PDF

Different profiles of neurocognitive impairment in patients with hepatitis B and C virus infections.

Sci Rep 2022 Jun 23;12(1):10625. Epub 2022 Jun 23.

Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

The direct impact of chronic hepatitis B and hepatitis C on neurocognition remains elusive due to the frequent comorbidities, and the domains of the neurocognitive functions affected have rarely been investigated comprehensively. We cross-sectionally assessed the neurocognitive functions of the individuals with chronic hepatitis B, chronic hepatitis C, treated chronic hepatitis C with a sustained virologic response, and their healthy control counterparts. Laboratory examinations were used to investigate the impact of inflammation on neurocognition, exclude the medical conditions that could interfere with neurocognition assessment, and assess liver function and fibrotic severity of the liver of the participants. Read More

View Article and Full-Text PDF

Dispensing of HIV and Hepatitis C Antivirals During COVID-19: An Interrupted Time-Series Analysis of U.S. National Data.

Am J Prev Med 2022 May 20. Epub 2022 May 20.

Department of Markets, Public Policy & Law, Boston University Questrom School of Business, Boston University, Boston, Massachusetts.

Introduction: Little is known about the potential changes in the dispensation of life-saving hepatitis C virus (HCV) and HIV antivirals after the initial U.S. outbreak of COVID-19. Read More

View Article and Full-Text PDF

COVID-19 After Treatment With Direct-acting Antivirals for HCV Infection and Decompensated Cirrhosis: A Case Report.

In Vivo 2022 Jul-Aug;36(4):1986-1993

Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.

Background: Eradication of hepatitis C virus (HCV) from chronic HCV-infected patients could improve liver function and prevent hepatocarcinogenesis in the long term. Eradication of HCV by direct-acting antivirals (DAAs) also leads to dynamic immunological changes. We report a case of recurrent coronavirus disease 2019 (COVID-19) that developed immediately after combination treatment with DAAs for HCV infection and decompensated cirrhosis. Read More

View Article and Full-Text PDF

[HIV/HCV Among Drug Users in Germany: Elimination Targets in the Mirror of Practice].

Gesundheitswesen 2022 Jun 23. Epub 2022 Jun 23.

Drogen, Haft, Frauen und Migration, Deutsche Aidshilfe e.V., Berlin, Germany.

Background: In 2016, the World Health Organization presented the first strategy for the elimination of viral hepatitis by 2030, following the goals of the Agenda 2030. Ending Acquired Immune Deficiency Syndrome (AIDS) by 2030 was also formulated as one of the Sustainable Development Goals and subsequently included and elaborated in the Joint United Nations Programme on HIV/AIDS (UNAIDS) strategy. People who inject drugs (PWID) are among the most vulnerable groups in terms of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection. Read More

View Article and Full-Text PDF

When are breakthrough therapies cost-effective?

J Manag Care Spec Pharm 2022 Jul;28(7):732-739

Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA.

An increasing proportion of novel drug approvals use accelerated pathways, with notable growth in the US Food and Drug Administration-designated breakthrough pathway in recent years. Breakthrough therapy (BT) designation suggests that these therapies offer substantial potential to improve health outcomes but their value for money is not fully understood, as BTs typically cost more than non-BTs (NBTs). To assess the economic value of BTs and factors associated with their reported value. Read More

View Article and Full-Text PDF

Implementation of a Controlled Human Infection Model for Evaluation of HCV Vaccine Candidates.

Hepatology 2022 Jun 23. Epub 2022 Jun 23.

Liver Center, GI Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

Hepatitis C virus (HCV) remains a major global health concern. Directly acting antiviral (DAA) drugs have transformed the treatment of HCV. However, it has become clear that without an effective HCV vaccine it will not be possible to meet the WHO targets of HCV viral elimination. Read More

View Article and Full-Text PDF